Stem Cell Transplant Patients at Higher Risk of Heart Disease

According to a study published online in Blood, the journal of the American Society of Hematology, stem cell transplant patients are at a higher risk of developing heart disease.

Researchers from City of Hope hospital in Duarte, California, which runs one of the nation's busiest stem cell transplant programs, carried out a retrospective study of patients who underwent a hematopoietic stem cell transplant.

They found that these patients have a higher incidence of risk factors associated with cardiovascular disease, when compared to the public. This proved especially true for patients who survive an allogeneic transplant, and for patients who endure grades II-IV graft-versus-host disease (GVHD).

GVHD is a sometimes fatal complication of a stem cell transplant in which the graft, the donor organ, rejects the patient (as opposed to it being the other way around).

Factors Contributing to Heart Disease in Stem Cell Transplant Patients

Researchers think there are two primary factors contributing to heart disease in these patients:

    -Conditioning chemotherapy and radiation prior to transplant
    -Treatment for GVHD

Furthermore, the risk of actually developing cardiovascular disease was found to be higher among patients who had all of the cardiovascular risk factors studied—hypertension, diabetes, and dyslipidemia—and they developed them earlier than the general public.

"Our study sought to better determine the specific factors before and after transplant that can lead to heart disease in a large group of transplant recipients," the researchers said.

Source: Medpage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap